Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK6 | P43250 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.33 |
| ▸ | HPGD | P15428 | 4/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4509405 | 0.70 | CYP1A2 (0.44) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL634465 | 0.70 | GRK6 (0.50) | GRK6CYP1A2ERBB2FYNMAOA | |
| SCHEMBL634466 | 0.68 | CYP1A2 (0.42) | GRK6CYP1A2ERBB2FYNMAOA | |
| SCHEMBL8112 | 0.67 | GRK6 (1.00) | GRK6CYP1A2ALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL29778809 | 0.67 | GRK6 (1.00) | GRK6CYP1A2ALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL30919341 | 0.67 | GRK6 (0.50) | GRK6CYP1A2ALDH1A1HSD17B10HPGD | |
| Bromide SCHEMBL31741343 | 0.66 | GRK6 (0.96) | GRK6CYP1A2ALDH1A1HSD17B10HPGD | |
| Hydrochloric Acid SCHEMBL11423019 | 0.66 | GRK6 (0.96) | GRK6CYP1A2ALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL30295512 | 0.65 | CYP1A2 (0.46) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL12280879 | 0.65 | CYP1A2 (0.46) | CYP1A2ERBB2FYNMAOAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6376655-B1 | APPLYING EXTERNAL STIMULATION; OPTICAL ANISOTROPY | RISO NATIONAL LABORATORY (DK) | 2002-04-23 | — | — | US | claimed |
| EP-1507778-B1 | ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES | UNIV TROBE (AU) | 2012-02-22 | — | — | EP | disclosed |
| US-20090156630-A1 | ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES | BAGULEY BRUCE CHARLES | 2009-06-18 | — | — | US | disclosed |
| US-7504507-B2 | Anti-tumour polycyclic carboxamides | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-03-17 | — | — | US | disclosed |
| US-20050245561-A1 | Anti-tumour polycyclic carboxamides | AUCKLAND UNISERVICES LIMITED (NZ) | 2005-11-03 | — | — | US | disclosed |
| US-6376655-B1 | APPLYING EXTERNAL STIMULATION; OPTICAL ANISOTROPY | RISO NATIONAL LABORATORY (DK) | 2002-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156630-A1 | ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES | MKI67, MCL1, CCNI | GRK6 4822/4885CYP1A2 1244/4885ERBB2 912/4885 |
| US-20050245561-A1 | Anti-tumour polycyclic carboxamides | MKI67, MCL1, CCNI | GRK6 4814/4885CYP1A2 1358/4885ERBB2 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.